Rotavirus Vaccines and Vaccination

Viral Gastroenteritis: Molecular Epidemiology and Pathogenesis

Volumn , Issue , 2016, Pages 301-328

  Vesikari, T ^a  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

Author keywords

Gut intussusception; RIT4237; RotaShield, RotaTeq, Rotavac, Rotavin M1; Rotavirus vaccines; Vaccine development; Vaccine effectiveness; Vaccine efficacy; Vaccine recommendations

Indexed keywords

EID: 84987786813     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-802241-2.00015-8     Document Type: Chapter

References (125)

1. Aiyegbo M.S., Sapparapu G., Spiller B.W., Eli I.M., Williams D.R., Kim R., Lee D.E., Liu T., Li S., Woods V.L., Nannemann D.P., Meiler J., Stewart P.L., Crowe J.E. Human rotavirus VP6-specific antibodies mediate intracellular neutralization by binding to a quaternary structure in the transcriptional pore. PLoS One 2013, 8:e61101.
2. Armah G.E., Sow S.O., Breiman R.F., Dallas M.J., Tapia M.D., Feikin D.R., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(9741):606-614.
3. Armah G.E., Kapikian A.Z., Vesikari T., Cunliffe N., Jacobson R.M., Burlington D.B., Ruiz L.P. Efficacy, immunogenicity, and safety of two doses of a tetravalent rotavirus vaccine RRV-TV in Ghana with the first dose administered during the neonatal period. J. Infect. Dis. 2013 Aug 1, 208(3):423-431.
4. Atchison C.J., Stowe J., Andrews N., et al. Rapid declines in age group-specific rotavirus infection and acute gastroenteritis among vaccinated and unvaccinated individuals within 1 year of rotavirus vaccine introduction in England and Wales. J. Infect. Dis. 2016, 213.
5. Azevedo M.S., Gonzalez A.M., Yuan L., Jeong K.I., Iosef C., Van Nguyen T., Lovgren-Bengtsson K., Morein B., Saif L.J. An oral versus intranasal prime/boost regimen using attenuated human rotavirus or VP2 and VP6 virus-like particles with immunostimulating complexes influences protection and antibody-secreting cell responses to rotavirus in a neonatal gnotobiotic pig model. Clin. Vaccine Immunol. 2010, 17:420-428.
6. Azevedo M.P., Vlasova A.N., Saif L.J. Human rotavirus virus-like particle vaccines evaluated in a neonatal gnotobiotic pig model of human rotavirus disease. Expert Rev. Vaccines 2013, 12:169-181.
7. Bakare N., Menschik D., Tiernan R., Hua W., Martin D. Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS). Vaccine 2010, 28(40):6609-6612.
8. Bernstein D.I., Smith V.E., Sander D.S., Pax K.A., Schiff G.M., Ward R.L. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. J. Infect. Dis. 1990, 162(5):1055-1062.
9. Bernstein D.I., Sack D.A., Rothstein E., Reisinger K., Smith V.E., O'Sullivan D., Spriggs D.R., Ward R.L. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet 1999, 354(9175):287-290.
10. Bhandari N., Rongsen-Chandola T., Bavdekar A., John J., Antony K., Taneja S., et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet 2014, 383(9935):2136-2143.
11. Bishop R.F., Davidson G.P., Holmes I.H., Ruck B.J. Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet 1973, 2(7841):1281-1283.
12. Blazevic V., Lappalainen S., Nurminen K., Huhti L., Vesikari T. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine 2011, 29:8126-8133.
13. Blutt S.E., Warfield K.L., O'Neal C.M., Estes M.K., Conner M.E. Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs). Vaccine 2006, 24:1170-1179.
14. Braeckman T., Van Herck K., Meyer N., et al. RotaBel Study Group. Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. BMJ 2012, 345:e4752.
15. Burns J.W., Siadat-Pajouh M., Krishnaney A.A., Greenberg H.B. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996, 272:104-107.
16. Ceyhan M., Kanra G., Seçmeer G., Midthun K., Davidson B.L., Zito E.T., Vesikari T. Take of rhesus-human reassortant tetravalent rotavirus vaccine in breast-fed infants. Acta Paediatr. 1993, 82(3):223-227.
17. Clark H.F., Furukawa T., Bell L.M., Offit P.A., Perrella P.A., Plotkin S.A. Immune response of infants and children to low-passage bovine rotavirus (strain WC3). Am. J. Dis. Child 1986, 140:350-356.
18. Clark H.F., Offit P.A., Ellis R.W., Eiden J.J., Krah D., Shaw A.R., Pichichero M., Treanor J.J., Borian F.E., Bell L.M., Plotkin S.A. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J. Infect. Dis. 1996, 174(Suppl. 1):S73-S80.
19. Clark H.F., Burke C.J., Volkin D.B., Offit P., Ward R.L., Bresee J.S., Dennehy P., Gooch W.M., Malacaman E., Matson D., Walter E., Watson B., Krah D.L., Dallas M.J., Schödel F., Kaplan KM, Heaton P. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatr. Infect. Dis. J. 2003, 22:914-920.
20. Clark H.F., Bernstein D.I., Dennehy P.H., Offit P., Pichichero M., Treanor J., Ward R.L., Krah D.L., Shaw A., Dallas M.J., Laura D., Eiden J.J., Ivanoff N., Kaplan K.M., Heaton P. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J. Pediatr. 2004, 144:184-190.
21. Correia J.B., Patel M.M., Nakagomi O., et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J. Infect. Dis. 2010, 20:363-369.
22. Corthésy B., Benureau Y., Perrier C., Fourgeux C., Parez N., Greenberg H., Schwartz-Cornil I. Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. J. Virol. 2006, 80:10692-10699.
23. Danchin M., Kirkwood C.D., Lee K.J., Bishop R.F., Watts E., Justice F.A., et al. Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine. Vaccine 2013, 31(23):2610-2616.
24. Das B.K., Gentsch J.R., Hoshino Y., Ishida S., Nakagomi O., Bhan M.K., et al. Characterization of the G serotype and genogroup of New Delhi newborn rotavirus strain 116E. Virology 1993, 197(1):99-107.
25. Delem A., Lobmann M., Zygraich N. A bovine rotavirus developed as a candidate vaccine for use in humans. J. Biol. Stand. 1984, 12:443-445.
26. Donato C.M., Ch'ng L.S., Boniface K.F., Crawford N.W., Buttery J.P., Lyon M., Bishop R.F., Kirkwood C.D. Identification of strains of RotaTeq rotavirus vaccine in infants with gastroenteritis following routine vaccination. J. Infect. Dis. 2012, 206(3):377-383.
27. El-Attar L., Oliver S.L., Mackie A., Charpilienne A., Poncet D., Cohen J., Bridger J.C. Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease. Vaccine 2009, 27:3201-3208.
28. Fang A.Y., Tingay D.G. Early observations in the use of oral rotavirus vaccination in infants with functional short gut syndrome. J. Paediatr. Child Health 2012, 48(6):512-516.
29. Feng N., Lawton J.A., Gilbert J., Kuklin N., Vo P., Prasad B.V., Greenberg H.B. Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP6-specific IgA mAb. J. Clin. Inves. 2002, 109:1203-1213.
30. Flewett T.H., Bryden A.S., Davies H. Letter. Virus particles in gastroenteritis. Lancet 1973, 2:1497.
31. Flores J., Perez-Schael I., Gonzalez M., Garcia D., Perez M., Daoud N., Cunto W., Chanock R.M., Kapikian A.Z. Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants. Lancet 1987, 1(8538):882-884.
32. Fu C., He Q., Xu J., Xie H., Ding P., Hu W., et al. Effectiveness of the Lanzhou lamb rotavirus vaccine against gastroenteritis among children. Vaccine 2012, 31(1):154-158.
33. Gastañaduy P.A., Curns A.T., Parashar U.D., Lopman B.A. Gastroenteritis hospitalizations in older children and adults in the United States before and after implementation of infant rotavirus vaccination. JAMA 2013, 310:851-853.
34. Giammanco G., De Grandi V., Lupo L., Mistretta A., Pignato S., Teuween D., Bogaerts H., Andre F.E. Interference of oral poliovirus vaccine on RIT 4237 oral rotavirus vaccine. Eur. J. Epidemiol. 1988, 4(1):121-123.
35. Gothefors L., Wadell G., Juto P., Taniguchi K., Kapikian A.Z., Glass R.I. Prolonged efficacy of rhesus rotavirus vaccine in Swedish children. J. Infect. Dis. 1989, 159(4):753-757.
36. Goveia M.G., Rodriguez Z.M., Dallas M.J., Itzler R.F., Boslego J.W., Heaton P.M., DiNubile M.J., REST Study Team Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr. Infect. Dis. J. 2007, 26(12):1099-1104.
37. Groome M.J., Moon S.S., Velasquez D., Jones S., Koen A., van Niekerk N., Jiang B., Parashar U.D., Madhi S.A. Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa. Bull. World Health Organ. 2014, 92(4):238-245.
38. Groome M.J., Page N., Cortese M.M., et al. Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: a case-control study. Lancet Infect. Dis. 2014, 14:1096-1104.
39. Hanlon P., Hanlon L., Marsh V., Byass P., Shenton F., Hassan-King M., et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1987, 1(8546):1342-1345.
40. Harris, V.C., 2015. Role of the intestinal microbiota in the uptake of rotavirus vaccines. Abstract, 4th European Rotavirus Expert Meeting on Rotavirus Vaccine. Santiago de Compostela, Spain, 23-25 March 2015.
41. Hemming M., Räsänen S., Huhti L., Paloniemi M., Salminen M., Vesikari T. Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland. Eur. J. Pediatr. 2013, 172(6):739-746.
42. Hemming M., Vesikari T. Vaccine-derived human-bovine double reassortant rotavirus in infants with acute gastroenteritis. Pediatr. Infect. Dis. J. 2012, 31(9):992-994.
43. Istrate C., Hinkula J., Charpilienne A., Poncet D., Cohen J., Svensson L., Johansen K. Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice. Vaccine 2008, 26:4594-4601.
44. Iwata S., Nakata S., Ukae S., Koizumi Y., Morita Y., Kuroki H., Tanaka Y., Shizuya T., Schödel F., Brown M.L., Lawrence J. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial. Hum. Vaccin. Immunother. 2013, 9(8):1626-1633.
45. Javid P.J., Sanchez S.E., Jacob S., McNeal M.M., Horslen S.P., Englund J.A. The safety and immunogenicity of rotavirus vaccination in infants with intestinal failure. J. Pediatric. Infect. Dis. Soc. 2014, 3(1):57-65.
46. Jiang B., Wang Y., Saluzzo J.F., Bargeron K., Frachette M.J., Glass R.I. Immunogenicity of a thermally inactivated rotavirus vaccine in mice. Hum. Vaccin. 2008, 4:143-147.
47. Joensuu J., Koskenniemi E., Pang X.L., Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997, 350(9086):1205-1209.
48. Justino M.C.A., Linhares A.C., Lanzieri T.M., et al. Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil. Pediatr. Infect. Dis. J. 2011, 30:396-401.
49. Kapikian A.Z., Flores J., Hoshino Y., Glass R.I., Midthun K., Gorziglia M., Chanock R.M. Rotavirus: the major etiologic agent of severe infantile diarrhea may be controllable by a "Jennerian" approach to vaccination. J. Infect. Dis. 1986, 153(5):815-822.
50. Karafillakis E., Hassounah S., Atchison C. Effectiveness and impact of rotavirus vaccines in Europe, 2006-2014. Vaccine 2015, 33(18):2097-2107.
51. Kawai K., O'Brien M.A., Goveia M.G., Mast T.C., El Khoury A.C. Burden of rotavirus gastroenteritis and distribution of rotavirus strains in Asia: a systematic review. Vaccine 2012, 30:1244-1254.
52. Kawamura N., Tokoeda Y., Oshima M., Okahata H., Tsutsumi H., Van Doorn L.J., Muto H., Smolenov I., Suryakiran P.V., Han H.H. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine 2011, 29(37):6335-6341.
53. Kompithra R.Z., Paul A., Manoharan D., Babji S., Sarkar R., Mathew L.G., et al. Immunogenicity of a three dose and five dose oral human rotavirus vaccine (RIX4414) schedule in south Indian infants. Vaccine 2014, 32(Suppl. 1):A129-A133.
54. Lanata C.F., Black R.E., del Aguila R., Gil A., Verastegui H., Gerna G., et al. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. J. Infect. Dis. 1989, 159(3):452-459.
55. Lappalainen S., Pastor A.R., Tamminen K., López-Guerrero V., Esquivel-Guadarrama F., Palomares L.A., Vesikari T., Blazevic V. Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo. Hum. Vaccin. Immunother. 2014, 10(7):2039-2047.
56. ®), in Kenya, including among HIV-infected and HIV-exposed infants. Vaccine 2012, 30(Suppl. 1):A61-A70.
57. Lepault J., Petitpas I., Erk I., Navaza J., Bigot D., Dona M., Vachette P., Cohen J., Rey F.A. Structural polymorphism of the major capsid protein of rotavirus. EMBO J. 2001, 20:1498-1507.
58. Leshem E., Lopman B., Glass R., et al. Distribution of rotavirus strains and strain-specific effectiveness of the rotavirus vaccine after its introduction: a systematic review and meta-analysis. Lancet Infect. Dis 2014, 14(9):847-856.
59. Li D., Xu Z., Xie G., Wang H., Zhang Q., Sun X., Guo N., Pang L., Duan Z. Genotype of Rotavirus Vaccine Strain LLR in China is G10P[15]]. Bing Du Xue Bao 2015, 31(2):170-173.
60. Liu L., Oza S., Hogan D., Perin J., Rudan I., Lawn J.E., Cousens S., Mathers C., Black R.E. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet 2015, 385(9966):430-440.
61. Lopman B.A., Curns A.T., Yen C., Parashar U.D. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J. Infect. Dis. 2011, 204:980-986.
62. Luan le T., Trang N.V., Phuong N.M., Nguyen H.T., Ngo H.T., Nguyen H.T., et al. Development and characterization of candidate rotavirus vaccine strains derived from children with diarrhoea in Vietnam. Vaccine 2009, 27(Suppl. 5):F130-F138.
63. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., Ngwira B., Victor J.C., Gillard P.H., Cheuvart B.B., Han H.H., Neuzil K.M. Effect of human rotavirus vaccine on severe diarrhea in African infants. N. Engl. J. Med. 2010, 362(4):289-298.
64. Madhi S.A., Kirsten M., Louw C., Bos P., Aspinall S., Bouckenooghe A., Neuzil K.M., Steele A.D. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial. Vaccine 2012, 30(Suppl. 1):A44-A51.
65. Maki M. A prospective clinical study of rotavirus diarrhoea in young children. Acta Paediatr. Scand. 1981, 70(1):107-113.
66. Markkula J., Hemming M., Vesikari T. Detection of vaccine-derived rotavirus strains in nonimmunocompromised children up to 3-6 months after RotaTeq vaccination. Pediatr. Infect. Dis. J. 2015, 34(3):296-298.
67. Marlow, R., Finn, A., Trotter, C., 2015. Quality of life impacts from rotavirus gastroenteritis on children and their families in the UK. Vaccine 33 (39), 5212-5216.
68. McClanahan S.D., Krause P.R., Uhlenhaut C. Molecular and infectivity studies of porcine circovirus in vaccines. Vaccine 2011, 29:4745-5453.
69. Midthun K., Greenberg H.B., Hoshino Y., Kapikian A.Z., Wyatt R.G., Chanock R.M. Reassortant rotaviruses as potential live rotavirus vaccine candidates. J. Virol. 1985, 53(3):949-954.
70. Moon S.S., Tate J.E., Ray P., Dennehy P.H., Archary D., Coutsoudis A., Bland R., Newell M.L., Glass R.I., Parashar U., Jiang B. Differential profiles and inhibitory effect on rotavirus vaccines of nonantibody components in breast milk from mothers in developing and developed countries. Pediatr. Infect. Dis. J. 2013, 32(8):863-870.
71. Murphy T.V., Gargiullo P.M., Massoudi M.S., Nelson D.B., Jumaan A.O., Okoro C.A., Zanardi L.R., Setia S., Fair E., LeBaron C.W., Wharton M., Livengood J.R. Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med. 2001, 344(8):564-572. Rotavirus Intussusception Investigation Team.
72. Omenaca F., Sarlangue J., Szenborn L., Nogueira M., Suryakiran P.V., Smolenov I.V., Han H.H. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr. Infect. Dis. J. 2012, 31:487-493. ROTA-054 Study Group.
73. Parashar U.D., Alexander J.P., Glass R.I. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2006, 55:1-13.
74. Patel N.C., Hertel P.M., Estes M.K., de la Morena M., Petru A.M., Noroski L.M., Revell P.A., Hanson I.C., Paul M.E., Rosenblatt H.M., Abramson S.L. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N. Engl. J. Med. 2010, 362(4):314-319.
75. Patel M.M., López-Collada V.R., Bulhões M.M., et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N. Engl. J. Med. 2011, 364(24):2283-2292.
76. Patel M., Steele A.D., Parashar U.D. Influence of oral polio vaccines on performance of the monovalent and pentavalent rotavirus vaccines. Vaccine 2012, 30(Suppl. 1):A30-A35.
77. Patel M., Glass R.I., Jiang B., Santosham M., Lopman B., Parashar U. A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J. Infect. Dis. 2013, 208(2):284-294.
78. Paternina-Caicedo A., Parashar U.D., Alvis-Guzmán N., De Oliveira L.H., Castaño-Zuluaga A., Cotes-Cantillo K., Gamboa-Garay O., Coronell-Rodríguez W., De la Hoz-Restrepo F. Effect of rotavirus vaccine on childhood diarrhea mortality in five Latin American countries. Vaccine 2015, 33:3923-3928.
79. Payne D.C., Edwards K.M., Bowen M.D., Keckley E., Peters J., Esona M.D., Teel E.N., Kent D., Parashar U.D., Gentsch J.R. Sibling transmission of vaccine-derived rotavirus (RotaTeq) associated with rotavirus gastroenteritis. Pediatrics 2010, 125(2):e438-e441.
80. Payne D.C., Boom J.A., Staat M.A., Edwards K.M., Szilagyi P.G., Klein E.J., Selvarangan R., Azimi P.H., Harrison C., Moffatt M., Johnston S.H., Sahni L.C., Baker C.J., Rench M.A., Donauer S., McNeal M., Chappell J., Weinberg G.A., Tasslimi A., Tate J.E., Wikswo M., Curns A.T., Sulemana I., Mijatovic-Rustempasic S., Esona M.D., Bowen M.D., Gentsch J.R., Parashar U.D. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011. Clin. Infect. Dis. 2013, 57(1):13-20.
81. Pérez-Schael I., Guntiñas M.J., Pérez M., Pagone V., Rojas A.M., González R., Cunto W., Hoshino Y., Kapikian A.Z. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N. Engl. J. Med. 1997, 337(17):1181-1187.
82. Phua K.B., Lim F.S., Lau Y.L., Nelson E.A., Huang L.M., Quak S.H., Lee B.W., van Doorn L.J., Teoh Y.L., Tang H., Suryakiran P.V., Smolenov I.V., Bock H.L., Han H.H. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population. Vaccine 2012, 30(30):4552-4557.
83. Ranucci C.S., Tagmyer T., Duncan P. Adventitious agent risk assessment case study: evaluation of RotaTeq for the presence of porcine circovirus. PDA J. Pharm. Sci. Technil. 2011, 65:589-598.
84. Rennels M.B., Glass R.I., Dennehy P.H., Bernstein D.I., Pichichero M.E., Zito E.T., Mack M.E., Davidson B.L., Kapikian A.Z. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. Pediatrics 1996, 97(1):7-13. United States Rotavirus Vaccine Efficacy Group.
85. Richardson V., Parashar U., Patel M. Childhood diarrhea deaths after rotavirus vaccination in Mexico. N. Engl. J. Med. 2011, 365(8):772-773.
86. Rodríguez-Limas W.A., Pastor A.R., Esquivel-Soto E., Esquivel-Guadarrama F., Ramírez O.T., Palomares L.A. Immunogenicity and protective efficacy of yeast extracts containing rotavirus-like particles: a potential veterinary vaccine. Vaccine 2014, 32:2794-2798.
87. Rongsen-Chandola T., Strand T.A., Goyal N., et al. Effect of withholding breastfeeding on the immune response to a live oral rotavirus vaccine in North Indian infants. Vaccine 2014, 32(Suppl. 1):A134-A139.
88. Ruiz-Palacios G.M., Pérez-Schael I., Velázquez F.R., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N. Engl. J. Med. 2006, 354(1):11-22.
89. Ruuska, T., 1991. Childhood Diarrhoea. Thesis, University of Tampere.
90. Ruuska T., Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand. J. Infect. Dis. 1990, 22(3):259-267.
91. Salinas B., Pérez Schael I., Linhares A.C., Ruiz Palacios G.M., Guerrero M.L., Yarzábal J.P., Cervantes Y., Costa Clemens S., Damaso S., Hardt K., De Vos B. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. Pediatr. Infect. Dis. J. 2005, 24(9):807-816.
92. Simonsen L., Viboud C., Elixhauser A., Taylor R.J., Kapikian A.Z. More on RotaShield and intussusception: the role of age at the time of vaccination. J. Infect. Dis. 2005, 192(Suppl. 1):S36-S43.
93. Soriano-Gabarro M., Mrukowicz J., Vesikari T., Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr. Infect. Dis. J. 2006, 25(Suppl.):7-11.
94. Steele A.D., Madhi S.A., Louw C.E., Bos P., Tumbo J.M., Werner C.M., Bicer C., De Vos B., Delem A., Han H.H. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. Pediatr. Infect. Dis. J. 2011, 30:125-130.
95. Steinhoff M.C. Rotavirus: the first five years. J. Pediatr. 1980, 96:611-622.
96. Stumpf K.A., Thompson T., Sánchez P.J. Rotavirus vaccination of very low birth weight infants at discharge from the NICU. Pediatrics 2013, 132:e662-e665.
97. Svensson L., Sheshberadaran H., Vene S., Norrby E., Grandien M., Wadell G. Serum antibody responses to individual viral polypeptides in human rotavirus infections. J. Gen. Virol. 1987, 68(Pt 3):643-651.
98. Svensson L., Sheshberadaran H., Vesikari T., Norrby E., Wadell G. Immune response to rotavirus polypeptides after vaccination with heterologous rotavirus vaccines (RIT 4237, RRV-1). J. Gen. Virol. 1987, 68(Pt 7):1993-1999.
99. Tate J.E., Burton A.H., Boschi-Pinto C., Steele A.D., Duque J., Parashar U.D., et al. 2008 Estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect. Dis. 2012, 12(2):136-141.
100. Tregnaghi M.W., Abate H.J., Valencia A., Lopez P., Da Silveira T.R., Rivera L., Rivera Medina D.M., Saez-Llorens X., Gonzalez Ayala S.E., De León T., Van Doorn L.J., Pilar Rubio M.D., Suryakiran P.V., Casellas J.M., Ortega-Barria E., Smolenov I.V., Han H.H. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatr. Infect. Dis. J. 2011, 30(6):e103-e108. Rota-024 Study Group.
101. Velazquez F.R., Matson D.O., Calva J.J., Guerrero L., Morrow A.L., Carter-Campbell S., et al. Rotavirus infections in infants as protection against subsequent infections. N. Engl. J. Med. 1996, 335(14):1022-1028.
102. Vesikari T. Rotavirus vaccination: a concise review. Clin. Microbiol. Infect. 2012, 18(Suppl. 5):57-63.
103. Vesikari T., Isolauri E., D'Hondt E., Delem A., André F.E., Zissis G. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984, 1:977-981.
104. Vesikari T., Isolauri E., D'Hondt E., Delem A., André F.E. Increased "take" rate of oral rotavirus vaccine in infants after milk feeding. Lancet 1984, 2:700.
105. Vesikari T., Isolauri E., Delem A., D'Hondt E., Andre F.E., Beards G.M., et al. Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. J. Pediatr. 1985, 107(2):189-194.
106. Vesikari T., Ruuska T., Bogaerts H., Delem A., André F. Dose-response study of RIT 4237 oral rotavirus vaccine in breast-fed and formula-fed infants. Pediatr. Infect. Dis. 1985, 4:622-625.
107. Vesikari T., Ruuska T., Delem A., André F.E. Oral rotavirus vaccination in breast- and bottle-fed infants aged 6 to 12 months. Acta Paediatr. Scand. 1986, 75:573-578.
108. Vesikari T., Kapikian A.Z., Delem A., Zissis G. A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children. J. Infect. Dis. 1986, 153:832-839.
109. Vesikari T., Karvonen A., Korhonen T., Espo M., Lebacq E., Forster J., et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 2004, 22:2836-2842.
110. Vesikari T., Clark H.F., Offit P.A., Dallas M.J., DiStefano D.J., Goveia M.G., Ward R.L., Schödel F., Karvonen A., Drummond J.E., DiNubile M.J., Heaton P.M. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 2006, 24:4821-4829.
111. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. 2006, 354:23-33.
112. Vesikari T., Karvonen A.V., Majuri J., Zeng S.Q., Pang X.L., Kohberger R., et al. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. J. Infect. Dis. 2006, 194:370-376.
113. Vesikari T., Karvonen A., Forrest B.D., Hoshino Y., Chanock R.M., Kapikian A.Z. Neonatal administration of rhesus rotavirus tetravalent vaccine. Pediatr. Infect. Dis. J. 2006, 25:118-122.
114. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370:1757-1763.
115. Vesikari T., Itzler R., Karvonen A., Korhonen T., Van Damme P., Behre U., Bona G., Gothefors L., Heaton P.M., Dallas M., Goveia M.G. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine 2009, 28(2):345-351.
116. Vesikari T., Karvonen A., Ferrante S.A., Ciarlet M. Efficacy of the pentavalent rotavirus vaccine, RotaTeq, in Finnish infants up to 3 years of age: the Finnish Extension Study. Eur. J. Pediatr. 2010, 169:1379-1396.
117. Vesikari T., Van Damme P., Giaquinto C., Dagan R., Guarino A., Szajewska H., Usonis V. European Society for Paediatric Infectious Diseases consensus recommendations for rotavirus vaccination in Europe: update 2014. Pediatr. Infect. Dis. J. 2015, 34:635-643.
118. Victoria J.G., Wang C., Jones M.S., Jaing C., McLoughlin K., Gardner S., Delwart E.L. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J. Virol. 2010, 84:6033-6040.
119. Vodopija I., Baklaic Z., Vlatkovic R., Bogaerts H., Delem A., Andre F.E. Combined vaccination with live oral polio vaccine and the bovine rotavirus RIT 4237 strain. Vaccine 1986, 4:233-236.
120. Walker C.L., Rudan I., Liu L., Nair H., Theodoratou E., Bhutta Z.A., O'Brien K.L., Campbell H., Black R.E. Global burden of childhood pneumonia and diarrhoea. Lancet 2013, 381:1405-1416.
121. Ward R.L., Clemens J.D., Knowlton D.R., Rao M.R., van Loon F.P., Huda N., et al. Evidence that protection against rotavirus diarrhea after natural infection is not dependent on serotype-specific neutralizing antibody. J. Infect. Dis. 1992, 166(6):1251-1257.
122. Wen X., Cao D., Jones R.W., Li J., Szu S., Hoshino Y. Construction and characterization of human recombinant VP8* subunit parenteral vaccine candidates. Vaccine 2012, 30:6121-6126.
123. Werther R.L., Crawford N.W., Boniface K., Kirkwood C.D., Smart J.M. Rotavirus vaccine induced diarrhea in a child with severe combined immune deficiency. J. Allergy Clin. Immunol. 2009, 124:600.
124. Rotavirus vaccines. Weekly Epid. Record 2013, 88:49-64. WHO position paper.
125. Zaman K., Dang D.A., Victor J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376(9741):615-623.